Immune-modulatory effects of dietary Yeast Beta-1,3/1,6-D-glucan
Tóm tắt
Từ khóa
Tài liệu tham khảo
Pillemer L, Schoenberg MD, Blum L, Wurz L: Properdin system and immunity. II. Interaction of the properdin system with polysaccharides. Science. 1955, 122 (3169): 545-549. 10.1126/science.122.3169.545.
Novak M, Vetvicka V: Beta-glucans, history, and the present: immunomodulatory aspects and mechanisms of action. J Immunotoxicol. 2008, 5: 47-57. 10.1080/15476910802019045.
Novak M, Vetvicka V: Glucans as biological response modifiers. Endocr Metab Immune Disord Drug Targets. 2009, 9: 67-75. 10.2174/187153009787582423.
Vetvicka V, Vetvickova J: beta1,3-glucan: silver bullet or hot air?. Open Glycoscience. 2010, 3: 1-6.
Zekovic DB, Kwiatkowski S, Vrvic MM, Jakovljevic D, Moran CA: Natural and modified (1–>3)-beta-D-glucans in health promotion and disease alleviation. Crit Rev Biotechnol. 2005, 25: 205-230. 10.1080/07388550500376166.
Vetvicka V, Vetvickova J: beta(1–3)-D-glucan affects adipogenesis, wound healing and inflammation. Orient Pharm Exp Med. 2011, 11: 169-175. 10.1007/s13596-011-0024-4.
Bohn JA, BeMiller JN: (1-3)-β-D-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydr Polym. 1995, 28 (1): 3-14. 10.1016/0144-8617(95)00076-3.
Brown GD, Gordon S: Immune recognition of fungal β-glucans. Cell Microbiol. 2005, 7: 471-479. 10.1111/j.1462-5822.2005.00505.x.
Chan GC, Chan WK, Sze DM: The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol. 2009, 2: 25-10.1186/1756-8722-2-25.
Volman JJ, Ramakers JD, Plat J: Dietary modulation of immune function by beta-glucans. Physiol Behav. 2008, 94: 276-284. 10.1016/j.physbeh.2007.11.045.
Kumar H, Kawai T, Akira S: Pathogen recognition by the innate immune system. Int Rev Immunol. 2011, 30: 16-34. 10.3109/08830185.2010.529976.
Ausubel FM: Are innate immune signaling pathways in plants and animals conserved?. Nat Immunol. 2005, 6: 973-979. 10.1038/ni1253.
Didierlaurent A, Simonet M, Sirard JC: Innate and acquired plasticity of the intestinal immune system. Cell Mol Life Sci. 2005, 62: 1285-1287. 10.1007/s00018-005-5032-4.
Brown GD, Herre J, Williams DL, Willment JA, Marshall AS, Gordon S: Dectin-1 mediates the biological effects of beta-glucans. J Exp Med. 2003, 197: 1119-1124. 10.1084/jem.20021890.
Rice PJ, Adams EL, Ozment-Skelton T, Gonzalez AJ, Goldman MP, Lockhart BE, Barker LA, Breuel KF, Deponti WK, Kalbfleisch JH, Ensley HE, Brown GD, Gordon S, Williams DL: Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther. 2005, 314: 1079-1086. 10.1124/jpet.105.085415.
Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ: Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement. 1987, 4: 61-74.
Kankkunen P, Teirila L, Rintahaka J, Alenius H, Wolff H, Matikainen S: (1,3)-beta-glucans activate both dectin-1 and NLRP3 inflammasome in human macrophages. J Immunol. 2011, 184: 6335-6342.
Seljelid R, Bögwald J, Lundwall A: Glycan stimulation of macrophages in vitro. Exp Cell Res. 1981, 131: 121-129. 10.1016/0014-4827(81)90413-4.
Sandula J, Machnova E: Mitogenic activity of particulate yeast b-(1,)-D-glucan and its water-soluble derivates. Int J Biol Macromol. 1995, 17: 323-327. 10.1016/0141-8130(96)81839-3.
Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG, Heard S, Keroack M, Caushaj P, Benotti P: A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg. 1994, 129: 1204-1210. 10.1001/archsurg.1994.01420350102014.
Babineau TJ, Marcello P, Swails W, Kenler A, Bistrian B, Forse RA: Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg. 1994, 220: 601-609. 10.1097/00000658-199411000-00002.
de Felippe JJ, Maciel FM, Soares AM, Mendes NF: Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1–3 polyglucose (glucan). Surg Gynecol Obstet. 1993, 177: 383-
Suzuki I, Hashimoto K, Ohno N, Tanaka H, Yadomae T: Immunomodulation by orally administered beta-glucan in mice. Int J Immunopharmacol. 1989, 11: 761-769. 10.1016/0192-0561(89)90130-6.
Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK, Ross GD: Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol. 2004, 173: 797-806. 10.4049/jimmunol.173.2.797.
Suzuki I, Tanaka H, Kinoshita A, Oikawa S, Osawa M, Yadomae T: Effect of orally administered beta-glucan on macrophage function in mice. Int J Immunopharmacol. 1990, 12: 675-684. 10.1016/0192-0561(90)90105-V.
Wojcik R: Effect of Biolex Beta-HP on phagocytic activity and oxidative metabolism of peripheral blood granulocytes and monocytes in rats intoxicated by cyclophosphamide. Pol J Vet Sci. 2010, 13: 181-188.
Małaczewska J, Wójcik R, Jung L, Siwicki AK: Effect of Biolex β-HP on selected parameters of specific and non-specific humoral and cellular immunity in rats. Bull Vet Inst Pulawy. 2010, 54: 75-80.
Tsukada C, Yokoyama H, Miyaji C, Ishimoto Y, Kawamura H, Abo T: Immunopotentiation of intraepithelial lymphocytes in the intestine by oral administrations of beta-glucan. Cell Immunol. 2003, 221: 1-5. 10.1016/S0008-8749(03)00061-3.
Vetvicka V, Terayama K, Mandeville R, Brousseau P, Kournikakis B, Ostroff G: Orally-administered yeast β1,3-glucan Prophylactically protects against anthrax infection and cancer in mice. J Am Nutraceutical Ass. 2002, 5 (2): 16-20.
Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR, Yan J: Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. Blood. 2011, 117: 6825-6836. 10.1182/blood-2011-02-339812.
Adams EL, Rice PJ, Graves B, Ensley HE, Yu H, Brown GD, Gordon S, Monteiro MA, Papp-Szabo E, Lowman DW, Power TD, Wempe MF, Williams DL: Differential high-affinity interaction of dectin-1 with natural or synthetic glucans is dependent upon primary structure and is influenced by polymer chain length and side-chain branching. J Pharmacol Exp Ther. 2008, 325: 115-123. 10.1124/jpet.107.133124.
Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, Bose N, Chan AS, Magee AS, Danielson ME, Weiss A, Vasilakos JP, Underhill DM: Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’. Nature. 2011, 472: 471-475. 10.1038/nature10071.
Wójcik R, Janowska E, Malaczewska J, Siwicki AK: Effect of β-1,3/1,6-D-glucan on the phagocytic activity and oxidative metabolism of peripheral blood granulocytes and monocytes in rats. Bull Vet Inst Pulawy. 2009, 53: 241-246.
Rychlik A, Nieradka R, Kander M, Nowicki M, Wdowiak M, Kolodziejska-Sawerska A: The effectiveness of natural and synthetic immunomodulators in the treatment of inflammatory bowel disease in dogs. Acta Vet Hung. 2013, 61: 297-308. 10.1556/AVet.2013.015.
Cohen S, Tyrrell DA, Smith AP: Psychological stress and susceptibility to the common cold. N Engl J Med. 1991, 325: 606-612. 10.1056/NEJM199108293250903.
Cohen S, Tyrrell DA, Smith AP: Negative life events, perceived stress, negative affect, and susceptibility to the common cold. J Pers Soc Psychol. 1993, 64: 131-140.
Auinger A, Riede L, Bothe G, Busch R, Gruenwald J: Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body’s defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. Eur J Nutr. 2013, Epub ahead of print
Graubaum H-J, Busch R, Stier H, Gruenwald J: A double-blind, randomized, placebo-controlled nutritional study using an insoluble yeast beta-glucan to improve the immune defense system. Food Nutr Sci. 2012, 3: 738-746. 10.4236/fns.2012.36100.
Kohl A, Gogebakan O, Mohlig M, Osterhoff M, Isken F, Pfeiffer AF, Weickert MO: Increased interleukin-10 but unchanged insulin sensitivity after 4 weeks of (1, 3)(1, 6)-beta-glycan consumption in overweight humans. Nutr Res. 2009, 29: 248-254. 10.1016/j.nutres.2009.03.002.
Dellinger EP, Babineau TJ, Bleicher P, Kaiser AB, Seibert GB, Postier RG, Vogel SB, Norman J, Kaufman D, Galandiuk S, Condon RE: Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group. Arch Surg. 1999, 134: 977-983. 10.1001/archsurg.134.9.977.
Feldman S, Schwartz HI, Kalman DS, Mayers A, Kohrman HM, Clemens R, Krieger D: Randomized phase II clinical trials of Wellmune WGP for immune support during cold and flu season. J Appl Res. 2009, 9: 30-42.
Talbott S, Talbott J: Effect of beta 1,3/1,6 glucan on upper respiratory tract infection symptoms and mood state in marathon athlets. J Sports Sci Med. 2009, 8: 509-515.
Talbott S, Talbott J: Beta 1,3/1,6 glucan decreases upper respiratory tract infection symptoms and improves psychological well-being in moderate to highly-stressed subjects. Agro Food Industry Hi-Tech. 2010, 21: 21-24.
Talbott S, Talbott J, Cox D: Beta-glucan supplement reduces URTIs (Upper Respiratory Tract Infections) and improves mood state in healthy stressed subjects. FASEB J. 2010, 24: 922-
Carpenter KC, Breslin WL, Davidson T, Adams A, McFarlin BK: Baker’s yeast beta-glucan supplementation increases monocytes and cytokines post-exercise: implications for infection risk?. Br J Nutr. 2013, 109 (3): 478-486. 10.1017/S0007114512001407.
Fuller R, Butt H, Noakes PS, Kenyon J, Yam TS, Calder PC: Influence of yeast-derived 1,3/1,6 glucopolysaccharide on circulating cytokines and chemokines with respect to upper respiratory tract infections. Nutrition. 2012, Epub ahead of print
Talbott SM, Talbott JA: Baker’s yeast beta-glucan supplement reduces upper respiratory symptoms and improves mood state in stressed women. J Am Coll Nutr. 2012, 31: 295-300. 10.1080/07315724.2012.10720441.
Lehne G, Haneberg B, Gaustad P, Johansen PW, Preus H, Abrahamsen TG: Oral administration of a new soluble branched beta-1,3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers. Clin Exp Immunol. 2006, 143: 65-69. 10.1111/j.1365-2249.2005.02962.x.
EFSA: EFSA panel on dietetic products, nutrition and allergies (NDA): scientific opinion on the substantiation of a health claim related to Yestimun® and immune responses pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA J. 2010, 8: 11-
EFSA: EFSA panel on dietetic products, nutrition and allergies (NDA): scientific opinion on the substantiation of a health claim related to Yestimun® and defence against pathogens in the upper respiratory tract pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal. 2013, 11: 12-
EFSA: Search link for EFSA Publications. 2014, http://www.efsa.europa.eu/en/publucations.htm ,
European Commission: EU Register on Nutrition and Health Claims. 2014, http://ec.europa.eu/nuhclaims/?event=search ,
Pajno GB, Passalacqua G, Salpietro C, Vita D, Caminiti L, Barberio G: Looking for immunotolerance: a case of allergy to baker’s yeast (Saccharomyces cerevisiae). Eur Ann Allergy Clin Immunol. 2005, 37: 271-272.
EFSA Panel on Dietetic Products NaAN: Scientific Opinion on the safety of ‘yeast beta-glucans’ as a Novel Food ingredient. EFSA J. 2011, 9: 2137-[2122 pp.]
Babicek K, Cechova I, Simon RR, Harwood M, Cox DJ: Toxicological assessment of a particulate yeast (1,3/1,6)-beta-D-glucan in rats. Food Chem Toxicol. 2007, 45: 1719-1730. 10.1016/j.fct.2007.03.013.
Di Luzio NR, Williams DL, McNamee RB, Edwards BF, Kitahama A: Comparative tumor-inhibitory and anti-bacterial activity of soluble and particulate glucan. Int J Cancer. 1979, 24: 773-779. 10.1002/ijc.2910240613.